Ratings Transcenta Holding Limited

Equities

6628

KYG9005B1041

Market Closed - Hong Kong S.E. Other stock markets 04:08:10 2024-05-21 am EDT			5-day change	1st Jan Change
1.85 ^HKD	0.00%		+3.93%	-48.47%

Apr. 30	Transcenta Holding Limited Announces Board and Nomination Changes	CI
Apr. 09	Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	MT

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
With an enterprise value anticipated at 6.03 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
TRANSCENTA HOLDING LIMITED	-48.47%	96.31M	-
ELI LILLY AND COMPANY	+37.78%	705B	C+
NOVO NORDISK A/S	+32.82%	583B	B
JOHNSON & JOHNSON	-3.51%	364B	C+
MERCK & CO., INC.	+19.94%	332B	B-
ABBVIE INC.	+5.14%	291B	C+
ASTRAZENECA PLC	+16.64%	238B	B+
ROCHE HOLDING AG	-4.13%	210B	A+
NOVARTIS AG	+10.63%	209B	B-
AMGEN INC.	+9.32%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes